Delving into the Latest Updates on MART-1 and gp100 antigens pulsed dendritic cell vaccine(NCI) with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine, Dendritic cell vaccine

Synonyms-

Target

gp100 x melan-A

Action

modulators

Mechanism

gp100 modulators(Melanocyte protein PMEL modulators), melan-A modulators(Melanoma antigen recognized by T-cells 1 modulators)

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal Diseases

Active Indication-

Inactive Indication

Melanoma recurrentMelanoma, Cutaneous MalignantMetastatic melanoma

Originator Organization

National Cancer Institute

Active Organization-

Inactive Organization

National Cancer Institute

License Organization-

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

RATIONALE: Vaccines made from white blood cells treated with antigens may make the body build an immune response to kill melanoma cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining vaccine therapy with interleukin-2 may kill more melanoma cells.
PURPOSE: This phase I/II trial is studying the side effects and how well giving vaccine therapy and interleukin-2 works compared to vaccine therapy alone in treating patients with metastatic melanoma that has not responded to previous therapy.

Start Date01 Apr 1997

Sponsor / Collaborator

National Cancer Institute

NCT00019890

/ CompletedPhase 2IIT

Phase II Randomized Study of CD34+ Derived or Peripheral Monocyte Derived Dendritic Cells Pulsed With MART-1 and gp100 Melanoma Antigens in Patients With High Risk Stage III or Completely Resected Metastatic Melanoma

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.
PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy in treating patients who have high-risk stage III or completely resected metastatic melanoma.

Start Date-

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with MART-1 and gp100 antigens pulsed dendritic cell vaccine(NCI)

Login to view more data

100 Translational Medicine associated with MART-1 and gp100 antigens pulsed dendritic cell vaccine(NCI)

Login to view more data

100 Patents (Medical) associated with MART-1 and gp100 antigens pulsed dendritic cell vaccine(NCI)

Login to view more data

100 Deals associated with MART-1 and gp100 antigens pulsed dendritic cell vaccine(NCI)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Melanoma recurrent	Phase 2	-	National Cancer Institute	05 Mar 2007
Melanoma, Cutaneous Malignant	Phase 2	United States	National Cancer Institute	01 Apr 1997
Metastatic melanoma	Phase 2	United States	National Cancer Institute	01 Apr 1997